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Macrophage/monocyte-derived cells appear to play an important role in the
regulation of extracellular matrix protein turnover, which is crucial to the
maintenance of connective tissue homeostasis as organisms age (1, 2). Receptor-
mediated endocytosis by macrophages and monocytes is also involved in the
removal of deposited lipoproteins from arterial intima (3, 4) . The physiologic
ligand on selected macromolecules that is specifically recognized by macrophages
in vivo has not yet been identified, however.
In vitro, covalent modification of low-density lipoprotein (LDL)' by chemical
reagents such as acetic anhydride or maleic anhydride results in macrophage
recognition and uptake of these modified proteins (5), while modification of
albumin by treatment with formaldehyde results in similar recognition and
uptake by hepatic phagocytes (6). Although no significant in vivo formation of
either ligand has been demonstrated, specific, distinct receptors have been
isolated and characterized for both acetyl-LDL and formaldehyde albumin (7,
8) . The biological role of these receptors remains to be elucidated.
Recently (9, 10), a new membrane-associated macrophage receptor has been
identified that recognizes proteins modified by a common in vivo process, long-
term nonenzymatic reaction of glucose with proteins. This receptor specifically
recognizes advanced glycosylation endproducts (AGE), which form slowly from
initial Amadori glycosylation products through a series of further reactions,
rearrangements, and dehydrations (11, 12) . One of the AGE recognized by this
receptor, 2-furoyl-4-(5)-(2-furanyl)-1H-imidazole (17171), is a condensation product
oftwo glucose molecules and two lysine amino groups (13, 14). Scatchard analysis
of AGE-protein binding data has indicated that there are ~105 receptors per
macrophage, with an affinity constant (K,,) of 1 .75 X 107/M (10). These AGE
receptors are distinct from the mannose/fucose receptors involved in glycopro-
tein uptake (15), since yeast mannan does not compete with AGE-protein uptake
by macrophages (10). However, the possibility that the AGE-protein receptor is
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identical to other previously described scavenger receptors has not yet been
excluded .
In this report, we describe competition and crosscompetition experiments
between AGE-modified protein and a variety of previously described scavenger
receptor fgands . Furthermore, the specific pattern of AGE-protein receptor
inhibition by the polyanionic compounds polyinosinic acid, polyadenylic acid,
polyglutamic acid, polycyticylic acid, fucoidin, and heparin was assessed and
compared with that of acetyl-LDL . Similar experiments were performed using
proteins modified by the specific AGE, FFI . The data obtained indicate that the
macrophage receptor for glucose-modified proteins is distinct from previously
described scavenger receptors.
Materials and Methods
AGE-BSA was prepared by incubating BSA in 50mM glucose at 37°C and 4-6 wk, in
the presence of protease inhibitors (PMSF, 1 .5 mM ; EDTA, 0.5 mM) and antibiotics
(penicillin, 100 U/ml ; gentamicin, 40 mg/ml) as described previously (9) . Aliquots of
AGE-BSA were subjected to IEF and SDS-PAGE, and did not show any change in pI or
A wt as compared with unmodified BSA . Radioiodination was carried out by the method
of Fraker and Speck (16) . FFI-BSA and FFI-LDL were prepared by covalently coupling
FFI-hexanoic acid to BSA or freshly prepared human LDL using water soluble carbodi-
imide, as described in detail previously (10, 17) . Formaldehyde-treated albumin was
prepared by dissolving BSA in 0.45 M sodium carbonate (pH 10.0), followed by centrif-
ugation and the addition of formaldehyde solution (37% wt/vol) dropwise with stirring,
as previously reported (18) . After incubation at 37'C for I h, the solution was dialyzed
overnight against 0.15M NaCl, and then against distilled water at 4°C . After centrifuga-
tion at 20,000 g for 30 min at VC, C, the supernatant was ready for use . LDL was prepared
from pooled normolipidemic human serum by density gradient ultracentrifugation in a
vertical rotor (19, 20), and acetylated by repeated partial additions of acetic anhydride
(Fischer Scientific Co ., Springfield, NJ) for >1 h at 2° C, followed by dialysis against PBS
(5) . In all experiments, the same preparations of AGE-BSA, FFI-BSA, and acetyl-LDL
were used . Maleyl-BSA was prepared by dissolving BSA in 0.2 M Na2B 40 7 . The pH was
brought to 8 .5, and the mixture was combined with an excess of solid maleic anhydride
(Matheson, Coleman, and Bell, Norwood, OH) as previously described (5), until all acid
was liberated, then dialyzed overnight . PBS-BSA and PBS-LDL refer to unmodified BSA
and LDL in 0 .1 M PBS .
Mouse peritoneal macrophages were isolated as described before (9) from female NCS
mice (25-30 g) obtained from the Laboratory Animal Research Center facility of The
Rockefeller University . In the competition studies described below, each well (106 cells)
received 10,ug (150 nM) radiolabeled AGE-BSA (sp act, 286 cpm/ng), 10 tig (150 nM)
radiolabeled FFI-BSA (sp act, 358.1 cpm/ng), or 25 P,g (63 nM) labeled acetyl-LDL (sp
act, 272.0 cpm/ng) and the indicated amounts of unlabeled competitor . Competitors used
in experiments with radiolabeled AGE-BSA and FFI-BSA were unmodified BSA, unmod-
ified LDL, acetyl-LDL, maleyl-BSA, formaldehyde-treated BSA, fucoidin, polyinosinic
acid, polyadenylic acid, polyglutamic acid, polycytidylic acid, and heparin sodium . After
a 4-h incubation at 37°C, the amount of radiolabeled protein in the cells and the amount
of "'I-labeled TCA-soluble material in the medium were determined in triplicate . Com-
petition experiments with ' 2.I-acetyl-LDL were performed in the presence of increasing
concentrations of unlabeled acetyl-LDL, AGE-BSA, FFI-BSA, and FFI-LDL .
Results
Cellular uptake of radioiodinated AGE-BSA was not inhibited by the addition
of increasing amounts of unlabeled BSA, while it was supressed to 10% of control0
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FIGURE 1 .
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Mouse peritoneal macrophage uptake (A) and degradation (B) of "'I-AGE-BSA
in the presence of increasing concentrations of various competing unlabeled ligands: AGE-
BSA ("), PBS-BSA (O), FFI-BSA (A), formaldehyde-treated BSA (x), acetyl-LDL (Op), PBS-
LDL (®), maleyl-BSA (/). Each well in these studies received 10,ug (150 nM) labeled AGE-
BSA(286 cpm/ng) andtheindicatedamounts ofunlabeledcompetitor. Aftera 4-hincubation
at 37°C, the amount of radiolabeled protein in the cells (A) and the amount of '21I-labeled
TCA-soluble material in the medium (B) were determined in triplicate. Values are expressed
as percent of control. The 100% values were 1.9 ug/mg for uptake and 3.2 hg/mg for
degradation.
by addition of unlabeled AGE-BSA (Fig. 1 A). BSA chemically linked to the
specific advanced glycosylation endproduct FFI also supressed AGE-BSA uptake
to ^-20% of control. This suggests that the AGE receptor recognizes a specific
type of AGE structure having important homology with FFI.
In contrast, addition of unlabeled formaldehyde-modified BSA (f-BSA) did
not reduce cellular uptake of AGE-BSA (Fig. 1A), even at the highest concentra-
tion added (1 .0 mg/ml). Cellular uptake of AGE-BSA was similarly unaffected
by addition of increasing amounts of unmodified LDL. However, when compe-
tition experiments were performed using acetyl-LDL and maleyl-BSA, AGE-
BSA uptake wassuppressed to 23 and 25% of control values, respectively. Acetyl-
BSA was totally ineffective in inhibiting AGE-BSA uptake by the cells (data not
shown). The effects of these competitors on cellular degradation of AGE-BSA
paralleled those observed with cellular uptake (Fig. 1B). Identical competition
experiments performed using radiolabeled FFI-BSA in place of AGE-BSA gave
identical results for both uptake and degradation (Fig. 2) .
Although these data suggested that cellular uptake of AGE-BSA and uptake
of acetyl-LDL and maleyl-BSA might be mediated by the same membrane
receptor, it was equally likely that the observed competition reflected nonspecific
membrane effects of these strong polyanionic competitors.
To distinguish between these two possibilities, competition experiments were
performed using a series of highly negatively charged macromolecules, which
included those previously shown (21) to selectively compete with acetyl-LDL for
its bindingsite. The sulfated polysaccharide fucoidin strongly inhibits the binding
ofacetyl-LDL, for example, while other sulfated polysaccharides, such as heparin1304
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FIGURE 2 .
￿
Competitive inhibition of '25I-FFI-BSA uptake (A) and degradation (B)by mouse
peritoneal macrophages in the presence of increasing concentrations of competingunlabeled
compounds: AGE-BSA (0), PBS-BSA (O), FFI-BSA (A), formaldehyde-treated BSA (x), PBS-
LDL (®), acetyl-LDL (Op), maleyl-BSA ("). Each well received 10 ug (150 nM) of labeled FFI-
BSA (178 cpm/ng) andthe indicatedamountsof unlabeled competitor. Aftera 4-h incubation
at 37°C, the amount of radiolabeled protein in the cells (A) and the amount of "5I-labeled
TCA-soluble material in the medium (B) were determined in triplicate. Values are expressed
as percent of control. The 100% values were 0.132 kg/mg for uptake and 0.325 Ag/mg for
degradation .
and chondroitin sulfate A and C do not . In our experiments, fucoidin also
inhibited the cellular binding of both AGE-BSA and FFI-BSA by >75% of
control, with >50% inhibition observed at concentrations of 50 Ag/ml (Fig . 3) .
However, unlike acetyl-LDL, binding of both AGE-BSA and FFI-BSA was
inhibited at least to 50% of control by heparin . Comparison of the effects of a
number of other polyanions on AGE-BSA binding to its receptor with those
reported for acetyl-LDL revealed additional differences . Although both recep-
tors were inhibited by polyinosinic acid and not by polycytidylic or polyglutamic
acid, only binding to the AGE-BSA receptor was inhibited by polyadenylic acid .
These results suggested that the AGE-protein receptor, like several other
scavenger receptors, is sensitive to the effects of polyanionic compounds . How-
ever, the specificity of inhibition by these compounds is distinct from that which
has been previously described for receptor-mediated uptake of acetyl-LDL (21),
arterial wall cholesteryl-ester/protein complexes (22), #-VLDL (very low-density
lipoprotein) (23), and formaldehyde-albumin (6) .
To further examine the differences between the AGE-protein receptor and
the acetyl-LDL receptor, reciprocal crosscompetition experiments were per-
formed in which cellular uptake and degradation of radioiodinated acetyl-LDL
was evaluated in the presence of increasing concentrations of either unlabeled
AGE-BSA, unlabeled FFI-BSA (Fig. 4) or unlabeled FFI-LDL (not shown) . It
was not possible to evaluate AGE-LDL, since the length of incubation time
required for AGE formation on proteins (6-8 wk) precluded preparations of
nondenatured AGE-LDL . Cellular uptake and degradation of radiolabeled ace-
tyl-LDL was effectively inhibited by addition of unlabeled acetyl-LDL . In con-VLASSARA ET AL.
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FIGURE 3.
￿
Competitive inhibition of 12.11-AGE-BSA (top) and 1251-FFI-BSA (bottom) uptake
by mouse peritoneal macrophages in the presence of increasing concentrations of potential
polyanionic competitors: polyglutamic acid (O), polycytidylic acid (p), heparin (0), polyinosinic
acid (A), polyadenylic acid (/), and fucoidin (0). Each well received 10 t+g (150 nM) of labeled
AGE-BSA, 10 Ag (150 nM) labeled FFI-BSA, and the indicated amount of unlabeled compet-
itor. After incubation for 4 h at 37 ° C, the amount of radioactivity in the cells was determined
in triplicate. Values are expressed as percent of control. The 100% values were 2.2 jig/mg for
'251-AGE-BSA and 0.125 wg/mg for
percent
￿
uptake.
trast, neither unlabeled AGE-BSA, unlabeled FFI-BSA, nor unlabeled FFI-LDL
competed significantly with receptor-mediated uptake or degradation of acetyl-
LDL.
Discussion
The studies described in this report demonstrate that the AGE-protein recep-
tor is distinct from the previously described receptor for acetyl-LDL, although
the possibility that acetyl-LDL is internalized to some extent by the AGE-
receptor, as well as by its own receptor, cannot be excluded.
Negatively charged acetyl-LDL interfered with binding and degradation of
AGE-BSA and FFI-BSA. However, the specific pattern of AGE- and FFI-BSA
inhibition by polyanionic compounds was distinctly different from that of acetyl-
LDL (21). Furthermore, reciprocal competition experiments showed no inhibi-
tion of acetyl-LDL binding and degradation by either AGE-BSA, FFI-BSA, or
FFI-LDL.
These findings are consistent with the hypothesis that scavenger receptors are
structurally distinct but related entities that show varying degrees of sensitivity
to polyanionic compounds. The incubation conditions used in these experiments
were selected to accelerate the formation of advanced glycosylation endproducts
over a practical experimental period. Since it is the integral of glucose concen-
tration over time that determines the extent of advanced glycosylation endprod-
uct accumulation in vivo, with concentrations of glucose found in plasma (10
mM), this process would occur over a much longer period. That AGE formation
does occur in vivo has recently (25) been demonstrated in collagen from nondi-1306
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FIGURE 4.
￿
Competitive inhibition of "'I-acetyl-LDL (272 cpm/ng) uptake (top) and degra-
dation (bottom) by mouse peritoneal macrophages in thepresence of increasing concentrations
ofunlabeled acetyl-LDL, AGE-BSA (left) and FFI-BSA (right). Each well received 25 ug (63
nM) of labeled acetyl-LDL and the indicated amount of unlabeled ligand. After incubation
for4 h at 37°C, theamount of radioactivity in the cellsand the amountsof "5I-labeled TCA-
soluble material in the medium were determined in triplicate. Values are expressed as percent
of control. The 100% value was 0.283 jug/mg .
abetic subjects, where an age-dependent linear increase in AGE accumulation
was found over a period of years.
The macrophage scavenger receptor for glucose-modified proteins, the speci-
ficity of which is defined by these studies, may have a unique biological signifi-
cance, since it is the first such receptor that recognizes a ligand known to form
extensively in vivo (24, 25). All body proteins investigated to date have been
shown to form Schiff base and Amadori product adducts with glucose, in
proportion to time and plasma glucose concentration (14). Although accumula-
tion of these early nonenzymatic glycosylation products does not continue beyond
the several weeks necessary to reach chemical equilibrium (26, 27), Amadori
products on long-lived proteins such as collagen give rise over long periods of
time to advanced glycosylation endproducts (AGE), which are recognized by the
macrophage receptor described in this report (28). Via theAGE-proteinreceptor,
macrophages would selectively recognize a time-dependent signal of protein
modification, and thus degrade only senescent macromolecules. The AGE-
protein receptor could, by this mechanism, have an important role in the
regulation of extracellular protein turnover.
In vivo, the efficiency of this removal system is not complete, however, since
advanced glycosylation products continue to accumulate over an individual'sentire lifespan as a function of both chronologic age and plasma glucose (14, 24).
These accumulating AGE form intra- and intermolecular crosslinks (25, 29-31),
which lead to the reduced elasticity of arteries, heart, and lungs associated with
normal aging (31). Hyperglycemia-induced acceleration of this process may
explain the premature degeneration of several tissues that is characteristically
seen in long-term diabetes mellitus (32). In both normal aging and in diabetes,
the rate at which aging-associated tissue changes take place may be profoundly
affected by genetic and/or environmental factors that alter the efficiency of this
receptor-mediated removal process. Increased future understanding of AGE
receptor-mediated endocytosis should provide new insight into the common
mechanisms underlying normal and diabetes accelerated aging.
Summary
A high-affinity macrophage receptor has been identified that recognizes pro-
teins modified by a common in vivo process, long-term nonenzymatic reaction
of glucose with proteins (AGE proteins). This receptor for glucose-modified
proteins is now shown to be distinct from previously described scavenger recep-
tors, using competition and crosscompetition experiments between AGE-modi-
fied protein and a variety of in vitro-modified scavenger receptor ligands,
including unmodified BSA, unmodified low-density lipoproteins (LDL), acetyl-
LDL, maleyl-BSA, and formaldehyde-treated BSA. Furthermore, the specific
pattern of AGE-protein receptor inhibition by the polyanionic compounds poly-
inosinic acid, polyadenylic acid, polyglutamic acid, polycytidylic acid, fucoidin,
and heparin was distinctly different from that of acetyl-LDL .
By thus selectively recognizing a time-dependent in vivo protein modification,
macrophages may preferentially degrade senescent macromolecules, thereby
having an important role in the regulation of extracellular protein turnover.
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